Literature DB >> 30020266

A Prospective Randomized Crossover Study in Single Sided Deafness on the New Non-Invasive Adhesive Bone Conduction Hearing System.

Griet Mertens1,2, Annick Gilles1,2,3, Rajae Bouzegta1, Paul Van de Heyning1,2.   

Abstract

BACKGROUND: Recently, an adhesive bone conduction hearing system has been developed for conductive hearing loss or single-sided deafness (SSD). In SSD cases, this device may be a good solution for patients who are unsuitable for, or who do not wish to undergo, bone conduction implant or cochlear implant surgery. The study aimed to investigate the hearing outcomes with the adhesive hearing system in SSD. PURPOSE OF THE STUDY: The study aimed to investigate the hearing outcomes with the adhesive hearing system in SSD.
METHODS: A randomized crossover study was conducted in 17 SSD participants, using CROS (contralateral routing of signals) hearing aid as a control. Following outcome measurements were administered after a two-week trial: 1) Speech, Spatial and Qualities scale, Audio Processor Satisfaction Questionnaire, and a custom-made questionnaire about the use of the system, 2) sound localization, 3) speech perception in noise.
RESULTS: 70% of the SSD subjects reported that the adhesive hearing system was partially useful or better. Using the APSQ, the adhesive test device was evaluated equally as the control device. Sound localization improved with the adhesive test device and deteriorated with the control device. There was no improvement in speech perception in noise measured with the adhesive test device. Speech perception in noise (SSSDNNH) with the control device improved significantly.
CONCLUSION: To the best of our knowledge, this is the first study to report on the outcomes of the new adhesive system. Users' satisfaction of the adhesive hearing system was found to be comparable to the control device. Since the hearing outcomes vary highly between patients, trials with applicable hearing systems are recommended in SSD patients.

Entities:  

Mesh:

Year:  2018        PMID: 30020266     DOI: 10.1097/MAO.0000000000001892

Source DB:  PubMed          Journal:  Otol Neurotol        ISSN: 1531-7129            Impact factor:   2.311


  5 in total

1.  Sound localization in patients with bilateral vestibulopathy.

Authors:  Olivier Peetermans; Bieke Dobbels; Griet Mertens; Julie Moyaert; Raymond van de Berg; Olivier Vanderveken; Paul Van de Heyning; Angélica Pérez Fornos; Nils Guinand; Marc J W Lammers; Vincent Van Rompaey
Journal:  Eur Arch Otorhinolaryngol       Date:  2022-05-10       Impact factor: 2.503

2.  A Novel Bone Conduction Hearing System May Improve Memory Function in Children with Single Side Hearing loss: A Case-Control Study.

Authors:  Arianna Di Stadio; Laura Dipietro; Antonietta De Lucia; Valentina Ippolito; Reuven Ishai; Sabina Garofalo; Vincenzo Pastore; Giampietro Ricci; Antonio Della Volpe
Journal:  J Int Adv Otol       Date:  2020-08       Impact factor: 1.017

Review 3.  Systematic review of outcome domains and instruments used in designs of clinical trials for interventions that seek to restore bilateral and binaural hearing in adults with unilateral severe to profound sensorineural hearing loss ('single-sided deafness').

Authors:  Roulla Katiri; Deborah A Hall; Catherine F Killan; Sandra Smith; Pattarawadee Prayuenyong; Pádraig T Kitterick
Journal:  Trials       Date:  2021-03-20       Impact factor: 2.279

4.  Multicenter Results With an Active Transcutaneous Bone Conduction Implant in Patients With Single-sided Deafness.

Authors:  Alexander M Huber; Bernd Strauchmann; Marco D Caversaccio; Wilhelm Wimmer; Thomas Linder; Nicola De Min; John-Martin Hempel; Marlene Pollotzek; Henning Frenzel; Frauke Hanke; Christof Röösli
Journal:  Otol Neurotol       Date:  2022-02-01       Impact factor: 2.311

5.  Multicenter Clinical Investigation of a New Active Osseointegrated Steady-State Implant System.

Authors:  Emmanuel A M Mylanus; Håkan Hua; Stina Wigren; Susan Arndt; Piotr Henryk Skarzynski; Steven A Telian; Robert J S Briggs
Journal:  Otol Neurotol       Date:  2020-10       Impact factor: 2.619

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.